COVID-19: Changes to funding criteria for long-acting muscarinic agonists

We've temporarily removed the requirement for COPD diagnosis using spirometry for long-acting muscarinic agonists

Spirometry requirement changed for glycopyrronium, tiotropium, and umeclidinium

From 1 December 2021, we have temporarily removed the requirement for patients to have a diagnosis of COPD using spirometry, if spirometry is not possible due to COVID-19 restrictions.

Schedule listings

Glycopyrronium(external link)

Tiotropium bromide(external link)

Umeclidinium(external link)

We intend to return to previous endorsement once health services have stabilised to a point where it's practical to reinstate this requirement.

Who to contact

If you have questions about this funding change, email enquiry@pharmac.govt.nz